ADMA Biologics, Inc.

ADMA Biologics, Inc. is a commercial biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics. Operating primarily in the United States, the company focuses on treatments for patients with compromised immune systems and those at risk for certain infectious diseases. Its vertically integrated business model includes operating its own FDA-approved plasma collection centers to secure the raw materials needed for its therapies.

Financials

Earnings Transcripts

Leadership & board

Acquisitions

For the year ended December 31, 2025, two customers - BioCare, Inc. and Priority Healthcare Distribution, Inc. ("CuraScript") - together represented approximately 73% of ADMA's consolidated revenues.

You're subscribed.

Thanks for signing up.